Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

globenewswire.com
LLY Eli Lilly is mentioned as a key company in the Hepatocellular Carcinoma Market, which is related to liver cancer diagnostics. The article does not provide specific sentiment for the company itself. MRK Merck is listed as a key company in the Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma markets, both related to liver cancer diagnostics. No specific sentiment is provided for Merck. GSK GlaxoSmithKline is mentioned as a key company in the Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Non-Alcoholic Fatty Liver Disease markets. The article does not provide specific sentiment for GSK. BMY Bristol Myers Squibb is listed as a key company in the Hepatocellular Carcinoma and Liver Angiocarcinoma markets. The article does not provide specific sentiment for BMY. AZN AstraZeneca is mentioned as a key company in the Intrahepatic Cholangiocarcinoma, Liver Angiocarcinoma, and Non-Alcoholic Fatty Liver Disease markets. The article does not provide specific sentiment for AZN. PFE Pfizer is listed as a key company in the Liver Angiocarcinoma, Non-Alcoholic Fatty Liver Disease, and Metabolic Dysfunction-Associated Steatohepatitis markets. The article does not offer specific sentiment for PFE. NVO Novo Nordisk is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for NVO. REGN Regeneron Pharmaceuticals is listed as a key company in the Liver Angiocarcinoma market. The article does not provide specific sentiment for REGN. RDHL Redhill Biopharma is listed as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for RDHL. AGIO Agios Pharmaceuticals is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for AGIO. INCY Incyte Corporation is listed as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for INCY. CRBP Corcept Therapeutics is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for CRBP. BMRN BioMarin Pharmaceutical is listed as a key company in the Non-Alcoholic Fatty Liver Disease market. The article does not provide specific sentiment for BMRN. VKTX Viking Therapeutics is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for VKTX. RIGL Rigel Pharmaceuticals is listed as a key company in the Non-Alcoholic Fatty Liver Disease market. The article does not provide specific sentiment for RIGL. DTIL Detilaf is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for DTIL. CRDF Cardiff Oncology is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for CRDF. BIIB Biogen is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for BIIB. ALKS Alkermes is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for ALKS. EXAS Exact Sciences is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for EXAS. CLDX Celldex Therapeutics is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for CLDX. SRPT Sarepta Therapeutics is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for SRPT. TGTX TG Therapeutics is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for TGTX. ALNY Alnylam Pharmaceuticals is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for ALNY. CHKP Check Point Software Technologies is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for CHKP. TAK Takeda Pharmaceutical is mentioned as a key company in the Liver Angiocarcinoma market. The article does not provide specific sentiment for TAK. HHS Jiangsu Hengrui Medicine is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for HHS. SERV Servier is mentioned as a key company in the Liver Angiocarcinoma and Hepatocellular Carcinoma markets. The article does not provide specific sentiment for SERV. GILD Gilead Sciences is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for GILD. HRMY Hanmi Pharmaceutical is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for HRMY. IONS Ionis Pharmaceuticals is mentioned as a key company in the Metabolic Dysfunction-Associated Steatohepatitis market. The article does not provide specific sentiment for IONS. BH Boehringer Ingelheim is mentioned as a key company in the Non-Alcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis markets. The article does not provide specific sentiment for BH. FORM Forma Therapeutics is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for FORM. JNJ Janssen Pharmaceutical (part of Johnson & Johnson) is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for JNJ. GEN Genoscience Pharma is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for GEN. ABBV AbbVie is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for ABBV. AMGN Amgen is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for AMGN. CRSP CRISPR Therapeutics is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for CRSP. CHRD Chardan Healthcare Acquisition Corp. is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for CHRD. ADPT Adaptive Biotechnologies is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for ADPT. IMUX Immuron Limited is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for IMUX. ALGN Align Technology is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for ALGN. EXEL Exelixis is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for EXEL. VRTX Vertex Pharmaceuticals is mentioned as a key company in the Intrahepatic Cholangiocarcinoma market. The article does not provide specific sentiment for VRTX.

Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight New York, USA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

The liver cancer diagnostics market is expected to experience significant growth, driven by the rising global burden of hepatocellular carcinoma (HCC), increasing prevalence of chronic liver diseases such as hepatitis B, hepatitis C, cirrhosis, and non-alcoholic fatty liver disease (NAFLD), and growing emphasis on early cancer detection. Advances in diagnostic technologies, including liquid biopsy, circulating tumor DNA (ctDNA), blood-based biomarkers, AI-assisted imaging, and molecular diagnostics, are improving the accuracy and efficiency of liver cancer detection and monitoring.

DelveInsight’s Liver Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading liver cancer diagnostics companies’ market shares, challenges, liver cancer diagnostics market drivers, barriers, trends, and key liver cancer diagnostics companies in the market.

Liver Cancer Diagnostics Market Summary

To read more about the latest highlights related to the liver cancer diagnostics news, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/liver-cancer-diagnostics-market

Key Factors Contributing to the Rise in Growth of the Liver Cancer Diagnostics Market

Get a sneak peek at the liver cancer diagnostics market dynamics @ Liver Cancer Diagnostics Market Trends

Regional Liver Cancer Diagnostics Market Insights

North America

Europe

Asia-Pacific

To know more about why North America is leading the market growth in the liver cancer diagnostics market, get a snapshot of the Liver Cancer Diagnostics Market Share

Recent Developmental Activities in the Liver Cancer Diagnostics Market

What is Liver Cancer Diagnostics?

Liver cancer diagnostics refers to the range of medical tests and diagnostic procedures used to detect, characterize, and monitor liver cancer, particularly hepatocellular carcinoma (HCC), the most common primary liver cancer. Diagnosis typically involves a combination of medical history and physical examination, blood tests, liver function assessment, tumor biomarkers such as alpha-fetoprotein (AFP), and imaging techniques including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). In selected cases, a liver biopsy may be performed to confirm the diagnosis and determine the tumor’s histological characteristics. Advanced diagnostic approaches, including contrast-enhanced imaging, liquid biopsy, circulating tumor DNA, and other molecular or blood-based biomarkers, are also being developed to improve early detection, tumor characterization, treatment selection, and disease monitoring.

Liver Cancer Diagnostics Market Assessment

Which MedTech key players in the liver cancer diagnostics market are set to emerge as the trendsetter explore @ Top Liver Cancer Diagnostics Companies

Table of Contents

Interested in knowing the liver cancer diagnostics market share by 2034? Click to get a snapshot of the Liver Cancer Diagnostics Market Analysis

Related Reports

Hepatocellular Carcinoma Market

Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HCC companies including Eli Lilly, Merck, Genentech, GlaxoSmithKline, Bristol-Myers Squibb, and others.

Intrahepatic Cholangiocarcinoma Market

Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ICC companies including Compass Therapeutics, TransThera Sciences, Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Loxo Oncology, Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Merck, Glaxosmithkline, Eisai, Taiho Pharmaceutical, Servier, Bayer, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu Hengrui Medicine, Astrazeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array Biopharma, and others.

Liver Angiocarcinoma Market

Liver Angiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver angiocarcinoma companies including Bristol Myers Squibb, Merck & Co., Bayer AG, Eli Lilly and Company, Novartis AG, Ipsen, Pfizer Inc., Roche/Genentech, AstraZeneca, Eisai Co., Ltd., Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, GSK, Daiichi Sankyo, Zymeworks Inc., and others.

Non-Alcoholic Fatty Liver Disease Market

Non-Alcoholic Fatty Liver Disease Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NAFLD companies, including MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others.

Metabolic Dysfunction-Associated Steatohepatitis Market

Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.